minocycline and Enterocolitis--Neutropenic

minocycline has been researched along with Enterocolitis--Neutropenic* in 1 studies

Other Studies

1 other study(ies) available for minocycline and Enterocolitis--Neutropenic

Article	Year
Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. Cancer medicine, 2017, Volume: 6, Issue:7 Neutropenic enterocolitis (NEC) is an abdominal infection reported primarily in patients with acute myeloid leukemia (AML) following chemotherapy, especially cytarabine, a notable efficacious cytotoxic agent for AML remission. Specific data regarding the impact of different cytarabine schedules and/or antibacterial regimens for NEC are sparse. The aim of the study was to identify the predictors of outcome within 30 days of NEC onset. NEC episodes were retrospectively pinpointed among 440 patients with newly diagnosed AML hospitalized in our Institution, over a 10-year period, for receiving chemotherapy protocols with 100-6000 mg/m Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Drug Therapy, Combination; Enterocolitis, Neutropenic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minocycline; Mortality; Remission Induction; Tigecycline; Treatment Outcome; Ultrasonography; Workflow; Young Adult	2017

Article

Year

Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.

Cancer medicine, 2017, Volume: 6, Issue:7

Neutropenic enterocolitis (NEC) is an abdominal infection reported primarily in patients with acute myeloid leukemia (AML) following chemotherapy, especially cytarabine, a notable efficacious cytotoxic agent for AML remission. Specific data regarding the impact of different cytarabine schedules and/or antibacterial regimens for NEC are sparse. The aim of the study was to identify the predictors of outcome within 30 days of NEC onset. NEC episodes were retrospectively pinpointed among 440 patients with newly diagnosed AML hospitalized in our Institution, over a 10-year period, for receiving chemotherapy protocols with 100-6000 mg/m

Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Drug Therapy, Combination; Enterocolitis, Neutropenic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minocycline; Mortality; Remission Induction; Tigecycline; Treatment Outcome; Ultrasonography; Workflow; Young Adult

2017